New drug cocktail aims to beat tough lymphoma

NCT ID NCT07371923

Recruiting now Disease control Sponsor: Beijing Tongren Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding the drug zanubrutinib to a standard chemotherapy regimen (Pola-R-CHP) can improve outcomes for people with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who have high-risk features. About 50 participants will receive the combination for six cycles. The main goal is to see how many achieve a complete remission (no cancer detected).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanubrutinib (a BTK inhibitor) combined with polatuzumab, rituximab, cyclophosphamide, doxorubicin, and prednisone
What this could lead to: If successful, this could offer a more effective first-line treatment for high-risk DLBCL patients, potentially improving remission rates and reducing relapse.
What could go wrong: This is a small, early-phase (phase 2) single-center trial with no control group, so results may not be generalizable. The combination also carries risks of increased side effects from multiple drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)

Contacts and locations

Locations

Beijing Tongren Hospital
RECRUITING

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.